Active Biotech Investor Relations Material
Latest events
Investor Update
Active Biotech
Q1 2025
8 May, 2025
Q4 2024
13 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Active Biotech
Access all reports
Active Biotech AB is a Swedish biotechnology company focused on developing treatments for cancer and inflammatory diseases. Its key projects include Tasquinimod, an immunomodulatory molecule in clinical trials for multiple myeloma and myelofibrosis, and Laquinimod, aimed at treating inflammatory eye disorders like uveitis. Additionally, Naptumomab, an antibody-based immunotherapy, is being tested in combination with other treatments for solid tumors, including non-small cell lung cancer. The company is headquartered in Lund, Sweden, and is listed on the Nasdaq Stockholm.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ACTI
Country
🇸🇪 Sweden